- Home
- QTRX vs CLLS Comparison
QTRX vs CLLS Comparison
Compare QTRX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTRX
- CLLS
- Stock Information
- Founded
- QTRX 2007
- CLLS 1999
- Country
- QTRX United States
- CLLS France
- Employees
- QTRX N/A
- CLLS N/A
- Industry
- QTRX Biotechnology: Laboratory Analytical Instruments
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- QTRX Industrials
- CLLS Health Care
- Exchange
- QTRX Nasdaq
- CLLS Nasdaq
- Market Cap
- QTRX 261.7M
- CLLS 299.0M
- IPO Year
- QTRX 2017
- CLLS 2007
- Fundamental
- Price
- QTRX $4.97
- CLLS $2.99
- Analyst Decision
- QTRX Hold
- CLLS Buy
- Analyst Count
- QTRX 4
- CLLS 1
- Target Price
- QTRX $11.75
- CLLS $4.00
- AVG Volume (30 Days)
- QTRX 678.6K
- CLLS 77.9K
- Earning Date
- QTRX 11-11-2025
- CLLS 11-03-2025
- Dividend Yield
- QTRX N/A
- CLLS N/A
- EPS Growth
- QTRX N/A
- CLLS N/A
- EPS
- QTRX N/A
- CLLS N/A
- Revenue
- QTRX $125,784,000.00
- CLLS $63,438,000.00
- Revenue This Year
- QTRX N/A
- CLLS N/A
- Revenue Next Year
- QTRX $37.89
- CLLS $66.76
- P/E Ratio
- QTRX N/A
- CLLS N/A
- Revenue Growth
- QTRX N/A
- CLLS 223.09
- 52 Week Low
- QTRX $4.05
- CLLS $1.10
- 52 Week High
- QTRX $15.86
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- QTRX 54.13
- CLLS 61.44
- Support Level
- QTRX $4.25
- CLLS $2.88
- Resistance Level
- QTRX $4.60
- CLLS $3.35
- Average True Range (ATR)
- QTRX 0.23
- CLLS 0.17
- MACD
- QTRX 0.09
- CLLS 0.01
- Stochastic Oscillator
- QTRX 96.00
- CLLS 57.65
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.